Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
Ticlopidine ( Ticlodone : CAS 55142 - 85 - 3 ) is able to develop a positive effect on  claudication in patients affected by peripheral atherosclerotic disease ( PAD ) . It is also known that ticlopidine decreases fibrinogen levels in plasma . 15 PAD patients treated with ticlopidine for 3 months were studied , evaluating the drug 's effect both on maximum walking distance and on fibrinogen . Plasma fibrinogen as coagulable protein , fibrinogen antigen ( Partigen method ) , 125I-fibrinogen survival , euglobulin lysis time and plasminogen were determined with the aim of clarifying if the decrease of plasma fibrinogen induced by ticlopidine is due to an increased destruction of a decreased production of the molecule . The normal levels of all tests before and after therapy both in ticlopidine treated patients and in the control group ( acetylsalicylic acid + dipyridamol ) indicate that the two hypotheses are not true . It is proposed that ticlopidine developing the known effect in decreasing the binding of fibrinogen to platelets induces a decrease only of activated fibrinogen
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .